Vanguard Global Advisers
BCDA icon

Vanguard Global Advisers’s BioCardia BCDA Stock Holding History

Vanguard Global Advisers’s Portfolio BCDA Stock Details BCDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-268
Closed -$324 – 3650
2026
Q1 		$324 Buy
+268
New +$335 ﹤0.01% 3666

Other funds holding BCDA

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PP
Pingora Partners Wilson, Wyoming $171M AUM 60.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Vanguard Global Advisers's BCDA Position: Q2 2026 in Review

Vanguard Global Advisers sold out of BioCardia (BCDA) in Q2 2026, closing a stake of 268 shares — an estimated $324 sold.

Vanguard Global Advisers first reported a position in BCDA in Q1 2026 and held it in 1 quarter. The position peaked at $324 in Q1 2026. 21 funds tracked by Wall St. Rank hold BCDA as of Q2 2026.

  • Vanguard Global Advisers reported no remaining BioCardia position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 268 BioCardia shares in Q2 2026, an estimated $324.
  • Vanguard Global Advisers first reported a position in BioCardia in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's BioCardia position peaked at $324 in Q1 2026.
  • 21 funds tracked by Wall St. Rank held BioCardia as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.